Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach

Abal, 2003, Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action, Current Cancer Drug Targets, 3, 193, 10.2174/1568009033481967 Bosch, 2006, Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel, Clinical Cancer Research, 12, 5786, 10.1158/1078-0432.CCR-05-2649 Bournique, 2002, Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme, Drug Metabolism and Disposition, 30, 1149, 10.1124/dmd.30.11.1149 Chang, 2009, Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients, Annals of Oncology, 20, 272, 10.1093/annonc/mdn624 Crown, 2001, Docetaxel: overview of an active drug for breast cancer, The Oncologist, 6, 1, 10.1634/theoncologist.6-suppl_3-1 Dong, 2012, Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine, Journal of Cancer Research and Clinical Oncology, 138, 1197, 10.1007/s00432-012-1183-5 Edge, 2010, The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, Annals of Surgical Oncology, 17, 1471, 10.1245/s10434-010-0985-4 Esposito, 1999, Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients, Journal of Clinical Oncology, 17, 1132, 10.1200/JCO.1999.17.4.1132 Fromm, 2002, The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans, Advanced Drug Delivery Reviews, 54, 1295, 10.1016/S0169-409X(02)00064-9 Gehrmann, 2008, Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence?, Pharmacogenomics, 9, 969, 10.2217/14622416.9.7.969 Goh, 2002, Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies, Journal of Clinical Oncology, 20, 3683, 10.1200/JCO.2002.01.025 Hahn, 2003, Multifactor dimensionality reduction software for detecting gene–gene and gene–environment interactions, Bioinformatics, 19, 376, 10.1093/bioinformatics/btf869 Hanna, 2000, Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity, Cancer Research, 60, 3440 Hustert, 2001, The genetic determinants of the CYP3A5 polymorphism, Pharmacogenetics, 11, 773, 10.1097/00008571-200112000-00005 Kafka, 2003, Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer, Int J Oncol, 22, 1117 Kim, 2012, Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy, Cancer Chemotherapy and Pharmacology, 69, 1221, 10.1007/s00280-011-1816-4 Kuehl, 2001, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nature Genetics, 27, 383, 10.1038/86882 Marsh, 2006, Taxane pharmacogenetics, Personalized Medicine, 3, 33, 10.2217/17410541.3.1.33 Marsh, 2007, Pharmacogenetics and oncology treatment for breast cancer, Expert Opinion on Pharmacotherapy, 8, 119, 10.1517/14656566.8.2.119 Marsh, 2007, Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer, Pharmacogenomics Journal, 7, 362, 10.1038/sj.tpj.6500434 Miller, 1988, A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Research, 16, 1215, 10.1093/nar/16.3.1215 Rizzo, 2010, Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients, Breast Cancer Research and Treatment, 124, 593, 10.1007/s10549-010-1034-5 Salminen, 1999, Docetaxel: standard recommended dose of 100mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study, Journal of Clinical Oncology, 17, 1127, 10.1200/JCO.1999.17.4.1127 Shimada, 1999, Catalytic properties of polymorphic human cytochrome P450 1B1 variants, Carcinogenesis, 20, 1607, 10.1093/carcin/20.8.1607 Sissung, 2006, Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia, European Journal of Cancer, 42, 2893, 10.1016/j.ejca.2006.06.017 Sole, 2006, SNPStats: a web tool for the analysis of association studies, Bioinformatics, 22, 1928, 10.1093/bioinformatics/btl268 Sparreboom, 1997, Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine, Proceedings of the National Academy of Sciences of the United States of America, 94, 2031, 10.1073/pnas.94.5.2031 Tanabe, 2001, Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene, Journal of Pharmacology and Experimental Therapeutics, 297, 1137 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, Journal of the National Cancer Institute, 92, 205, 10.1093/jnci/92.3.205 Tran, 2006, Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms, Clinical Pharmacology and Therapeutics, 79, 570, 10.1016/j.clpt.2006.02.003 Tsai, 2009, Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms, Clinica Chimica Acta, 404, 160, 10.1016/j.cca.2009.03.038 Yamaguchi, 2006, Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer, International Journal of Gynecological Cancer, 16, 979, 10.1111/j.1525-1438.2006.00593.x